Impact of Brexit on patients and the life science industry examined
19 December 2017
The Health Committee hears from patient and research charities, and representatives of the pharmaceutical industry about the impact Brexit poses for the full life science process from research and development through to clinical trials, manufacture, market launch and pharmacovigilance.
- Watch Parliament TV: Brexit: the regulation of medicines, medical devices and substances of human origin
- Inquiry: Brexit – medicines, medical devices and substances of human origin
- Health Committee
Witnesses
Tuesday 19 December 2017, Grimond Room, Portcullis House
At 2.30pm
- Professor Alan Boyd, President of Faculty of Pharmaceutical Medicine, Academy of Medical Royal Colleges
- Emma Greenwood, Director of Policy, Cancer Research UK
- John Maingay, Director of Policy and Public Affairs, British Heart Foundation
- Sir Hugh Taylor, Co-Chair, Brexit Health Alliance
At 3.30pm
- Hugo Fry, UK General Manager, Sanofi
- Warwick Smith, Director General, British Generic Manufacturers Association
- Phil Thompson, President, Global Affairs, GlaxoSmithKline
- John Wilkinson, Partner, Cooley LLP
Further information
- Read the House of Commons Library briefing on Brexit and medicines regulation
- About Parliament: Select committees
- Visiting Parliament: Watch committees
Image: iStockphoto